G6PD deficiency in the COVID-19 pandemic: Ghost within Ghost

Al-Abdi, Sameer Y.; Al-Aamri, Maryam A.

doi:10.1016/j.hemonc.2020.04.002

Cited by 15 publications

(11 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study showed that sickle cell disease was present in 6 (7.3%) and G6PD deficiency in 27 (32.9%) of patients with no difference between asymptomatic and symptomatic patients. There was no previous study describing the association between G6PD deficiency and COVID-19 [ 43 ]. However, it was shown that G6PD deficiency enhances human coronavirus 229E experimental infection [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia

Al-Jishi¹,

Alhajjaj²,

Alkhabbaz³

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

Background The first case of COVID-19 infection in Saudi Arabia was reported in Qatif on March 2nd, 2020. Here, we describe the clinical characteristics of the initial COVID-19 patients in that area. Methods This is an observational study describing the clinical presentation, radiographic and laboratory data of COVID-19 cases. Results From March 1st, 2020 to April 5th, 2020 we identified a total of 82 adult COVID-19 patients. The median age of the patients was 50 years, with a range of 30 to 60 years and most of patients were female 54 (65.9%). Of all the patients, 29 (35.4%) were contacts and 43 (52.4%) were returning travelers, mainly from Iraq (65% of the total returning travelers). Comorbidities were present in 50% of patients, G6PD deficiency in 33%, hypertension in 27%, and diabetes mellitus in 26%. Chest radiographs were abnormal in 46% of symptomatic and 15.5% of asymptomatic patients (P value = 0.0035). Of all patients, 4 (4.87%) required intensive care admission. There was no significant difference in time to negative RT-PCR with mean days to negativity of 13.6 and 16.9 for asymptomatic and symptomatic group, respectively (P value = 0.42). Conclusions In the initial Epicenter of the COVID-19 in Saudi Arabia, the majority of the patients were asymptomatic and were returning travelers. Comorbidities were present in nearly half of the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia

Al-Jishi¹,

Alhajjaj²,

Alkhabbaz³

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

show abstract

“…Numerous underlying comorbidities or factors have been associated with a high risk of complications and mortality due to COVID-19, including (but not limited to) diabetes, heart disease, hypertension, obesity, asthma, chronic obstructive pulmonary disease (COPD), PD, renal or hepatic disorders, and also individuals that smoke, are immunocompromised, or have certain genetic factors e.g., glucose-6-phosphate dehydrogenase (G6PD) deficiency [ 250 , 251 , 252 , 253 , 254 , 255 ]. For most of these underlying risk factors, the reason for the intensification of disease symptoms is likely due to the chronic inflammatory and imbalanced redox state in the body and diminished respiratory function in lung disorders such as asthma, COPD, pulmonary hypertension, or due to smoking.…”

Section: How Might Ergothioneine Be Beneficial In Alleviating Covimentioning

confidence: 99%

“…One such example is individuals with G6PD deficiency, which has been suggested to cause vulnerability to coronavirus infection [ 254 , 255 ]. Reports have postulated that this is due to an imbalance of the endogenous antioxidant to the pro-oxidant pool in favor of the latter; hence, individuals with G6PD deficiency may not cope as well with the flux of ROS and inflammation [ 76 , 256 ].…”

Section: How Might Ergothioneine Be Beneficial In Alleviating Covimentioning

confidence: 99%

Could Ergothioneine Aid in the Treatment of Coronavirus Patients?

Cheah

Halliwell

2020

Antioxidants

View full text Add to dashboard Cite

Infection with SARS-CoV-2 causes the coronavirus infectious disease 2019 (COVID-19), a pandemic that has, at present, infected more than 11 million people globally. Some COVID-19 patients develop a severe and critical illness, spurred on by excessive inflammation that can lead to respiratory or multiorgan failure. Numerous studies have established the unique array of cytoprotective properties of the dietary amino acid ergothioneine. Based on studies in a range of in vitro and in vivo models, ergothioneine has exhibited the ability to modulate inflammation, scavenge free radicals, protect against acute respiratory distress syndrome, prevent endothelial dysfunction, protect against ischemia and reperfusion injury, protect against neuronal damage, counteract iron dysregulation, hinder lung and liver fibrosis, and mitigate damage to the lungs, kidneys, liver, gastrointestinal tract, and testis, amongst many others. When compiled, this evidence suggests that ergothioneine has a potential application in the treatment of the underlying pathology of COVID-19. We propose that ergothioneine could be used as a therapeutic to reduce the severity and mortality of COVID-19, especially in the elderly and those with underlying health conditions. This review presents evidence to support that proposal.

show abstract

“…Given the high prevalence of glucose‐6‐phosphate dehydrogenase (G6PD) deficiency in persons of African, Asian, and Mediterranean descent, 72 a potential association between G6PD deficiency and Covid‐19 has been suggested 73 . Due to its cellular redox state, G6PD deficiency increases viral replication and susceptibility to viral infections.…”

Section: Evidence For the Importance Of Vitamin D In Covid‐19mentioning

confidence: 99%

Vitamin D and Covid‐19: From potential therapeutic effects to unanswered questions

Teymoori‐Rad

Marashi

2020

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary Evidence suggests that vitamin D supplementation could potentially be effective either in treatment or prevention of coronavirus disease 2019 (Covid‐19). Indeed, several studies and trials have begun to investigate the impact of vitamin D supplementation on patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In this review, we focus on the potential mechanisms of vitamin D in the pathogenesis of Covid‐19. We consider whether deficiency of vitamin D may be one of the underlying biological factors that could explain the excess mortality seen among non‐Caucasians. We also raise several important questions which need to be addressed to provide a clear picture of the extent to which vitamin D supplementation may benefit patients with Covid‐19, particularly those with underlying risk factors.

show abstract

G6PD deficiency in the COVID-19 pandemic: Ghost within Ghost

Cited by 15 publications

References 6 publications

Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia

Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia

Could Ergothioneine Aid in the Treatment of Coronavirus Patients?

Vitamin D and Covid‐19: From potential therapeutic effects to unanswered questions

Contact Info

Product

Resources

About